Back to search results

PDA for Kidneys Study

This observational study, called the PDA for Kidneys Study, aims to learn more about how oxygen levels in a baby's kidneys are related to a condition called patent ductus arteriosus (PDA) and potential kidney injury. Researchers will use a device called Near Infrared Spectroscopy (NIRS) to monitor oxygen levels in the brain and kidneys of newborns during their first 72 hours of life. They will also look at heart ultrasounds and analyze urine samples. The main goal is to compare PDA heart measurements with kidney oxygen levels during the first week after birth. This study is for babies born before 32 weeks' gestation, who are 72 hours old or less, and are inpatients at Meriter Hospital, Inc. NICU. At least one parent must be able to give permission in English or Spanish. The study is currently unclear on its recruitment status.

Study design
This is an observational study with a planned enrollment of 45 participants. It is not a randomized or blinded study.
What's involved
Participants will have Near Infrared Spectroscopy (NIRS) sensors applied to their brain and kidney sites during the first 72 hours after birth to monitor regional tissue oxygenation.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures kidney hypoxia up to Day 7 of age.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06658496

PDA for Kidneys Study

Recruiting
Not specifiedAges 1–7Observational
University of Wisconsin, Madison
~45 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:Near Infrared Spectroscopy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Comparison of patent ductus arteriosus (PDA) echocardiography parameters to kidney hypoxia
Measured over Days 1 to 7 of age

Conditions

Patent Ductus Arteriosus
Congenital Heart Disease

Explore related trials

Congenital Heart DiseasePatent Ductus Arteriosus

NCT06658496

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Meriter Hospital, Inc.

    Madison, Wisconsinno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Matthew Harer, MD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

Paige Condit, MD
[email protected]
616-481-9914
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Delivered at \<32 weeks' gestation
≤72 hours of age
Inpatient at Meriter Hospital, Inc. NICU
At least one parent/guardian is able to provide parental permission in English or Spanish

Exclusion

Major congenital anomalies of kidney
Attending physician's discretion to not place NIRS sensors due to clinical concerns
In the PI or Co-I's medical opinion, there is a significant likelihood that the neonate would not survive the first 3 days of life
Birth parent aged \<18

What this trial measures

  • Comparison of patent ductus arteriosus (PDA) echocardiography parameters to kidney hypoxiaDays 1 to 7 of age

    Measured through continuous renal near infrared spectroscopy (NIRS) monitoring in neonates with a PDA to those without. Echos will be obtained every 48 hours during the first 7 days of age for a maximum of 3. RSO2 will be recorded until 7 days of age.